A proof-of-concept study to evaluate treatments’ efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative early breast cancer population
Phase: Phase II clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica Senologica
Drug: Giredestrant (GDC-9545); Abemaciclib (LY2835219); Inavolisib (GDC-0077)
Pathologies: Breast cancer
ClinicalTrials.gov: Read the details about clinical trials
The study is an international, open-label, Phase II clinical trial in patients with early-stage, hormone receptor (HR)-positive/HER2-negative breast cancer at high risk of recurrence, with no evidence of metastatic disease. Where eligible, patients initially enter a circulating tumor DNA (ctDNA) surveillance phase; subsequently, those who test ctDNA-positive may be assigned to different experimental treatment arms:
Arm A: giredestrant monotherapy, a selective estrogen receptor degrader (SERD) designed to block estrogen receptor signaling in tumor cells and reduce the risk of disease recurrence.
Arm B: combination of giredestrant and abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, aimed at enhancing control of tumor cell proliferation.
Arm C: combination of giredestrant and inavolisib, an inhibitor of the PI3K pathway, selected for patients with specific molecular alterations (PIK3CA mutations), targeting signaling pathways involved in tumor growth.
Arm D: standard endocrine therapy, with a possible subsequent treatment switch according to protocol, used as the reference arm to evaluate the efficacy of the experimental strategies.
The objective of the study is to assess whether ctDNA guided early intervention can eradicate molecular residual disease and reduce the risk of clinical recurrence compared with the standard approach based on adjuvant endocrine therapy alone.
Last update: 06/08/2026